Skip To Main Content
Vikram Deshpande on Muck Rack

Vikram Deshpande

Verified
Boston
As seen in: Journal of Clinical Pathology, Color Research & Application, Nature, Wiley Online Library, Cambridge University Press & Assessment, BMJ Oncology, Gut Journal, American Chemical Society, Medscape, Cell Press, Cell Stem Cell and
Professor, Harvard Medical School, Interim Chair of Pathology BIDMC. Editor-in-Chief, Journal of Clinical Pathology @JClinPath_BMJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vikram

Contact Vikram, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Basal crypt dysplasia in Barrett’s oesophagus: ready for prime time?

|
By Vikram Deshpande Verified, S L Meijer, Marnix Jansen
| Gut Journal Verified
Social Media Vikram Deshpande, LinkedIn @linkedin.com/in/vikram-deshpande-23149a168 Contributors VD and MJ conceptualised the manuscript and defined the clinical framework. VD, SL and MJ conducted the literature review and curated the illustrative examples. VD drafted the initial version of the manuscript. All authors contributed to the critical revision of the manuscript and approved the final version. VD supervised the project and is the guarantor of the article.
Open in Who Shared Issue with article?

Lineage plasticity driven by GATA6 loss fuels colorectal cancer metastasis

|
By Saori Goto, Vikram Deshpande Verified, Omer Yilmaz, Ömer H. Yilmaz, Norihiro Goto
| Cell Stem Cell Verified
Keywords colorectal cancer organoid metastasis Get full text access Log in, subscribe or purchase for full access. References 1. Dekker, E. ∙ Tanis, P.J. ∙ Vleugels, J.L.A. ... Colorectal cancer Lancet. 2019; 394:1467-1480 2. Siegel, R.L. ∙ Giaquinto, A.N. ∙ Jemal, A. Cancer statistics, 2024 CA A Cancer J. Clinicians. 2024; 74:12-49 3. Biller, L.H. ∙ Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review JAMA. 2021; 325:669-685 4. Hu, Z. ∙ Ding, J. ∙ Ma, Z. ...
Open in Who Shared Issue with article?

Tumour deposits in colorectal carcinoma are associated with immune evasion and dose-dependent adverse prognosis beyond nodal status

|
By soo lee, Berk Kaan Aktas, Avery Kim, Vikram Deshpande Verified, Monika Vyas, Osman Yilmaz
| Nature Verified
Abstract Tumour deposits (TDs) are established adverse prognostic features in colorectal carcinoma, yet their biologic significance and integration into current nodal staging systems remain controversial. Although TD burden has been associated with adverse prognosis beyond lymph node metastasis, its incremental staging relevance and the immune microenvironmental features of the primary tumour that may underlie the aggressive behaviour of TD-positive tumours remain incompletely defined.
Open in Who Shared Issue with article?
See all 42 licensed articles (44 Total)